Loading
A phase 1/2 trial of RC118-ADC, Toripalimab and RC148 in advanced solid tumours, run by RemeGen Co., Ltd., now recruiting.
A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06038396 by RemeGen Co., Ltd., with 48 participants planned, started 2023-08-03 and due to reach its primary completion in 2026-02-28. Interventions recorded: RC118, Toripalimab and RC148.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares RC118-ADC, RemeGen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares RC148, RemeGen, Toripalimab, Immune checkpoint inhibitors and the tag pipeline.
Shares Toripalimab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares RemeGen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares RemeGen, Toripalimab, Immune checkpoint inhibitors and the tag pipeline.
Shares RemeGen, Toripalimab, Immune checkpoint inhibitors and the tag pipeline.
Shares Toripalimab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares RemeGen, Toripalimab, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/